Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
about
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patientsA mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavirBMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agentsIn vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysisLow level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.Genotypic testing for human immunodeficiency virus type 1 drug resistance.HIV-1 protease inhibitors.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisComparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyLower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionComparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.Monotherapy with lopinavir/ritonavir.AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristicsPeripheral neuropathy in ART-experienced patients: prevalence and risk factorsMethodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Ritonavir-boosted protease inhibitors in HIV therapy.Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.Pharmacology and clinical experience with amprenavir.
P2860
Q24805626-CD10B181-1E35-4F2F-96C7-394030A726FBQ28344112-998F747F-37BB-4EBA-86F8-E9CA6F694A89Q28344472-2AF3AA19-D531-4E12-9201-EE0078FF2E5CQ28344594-AFB0C230-C490-404E-8DBB-B15F33DCA629Q28362780-254A650A-B204-4E5B-892C-5A21618ED30FQ28742423-2BB4EA35-8914-4EC0-8F97-6429E089626CQ33595278-4041396D-D5D8-4AEC-AC97-80B15DBACE8CQ33906239-87ED3DF5-5738-4A2D-A59B-BD6B0B49AC38Q33946920-8BA5E8EB-AD9F-4381-85C3-AB003D44B884Q34010283-7F565A2E-6426-4714-A7B8-96CAAF2260C7Q34481365-682EAE7B-27E6-4B35-A540-506E8CAA9C9AQ35872395-9B4E1863-8DD0-4B7F-B7EA-39CB7B9DB059Q36491065-E58DA6A8-87E6-4EF7-A401-1D8AEA334E65Q36618299-0473F8E8-D11D-4639-BE04-E32B0FB988DAQ36623603-C9B2D13F-493D-47C6-AEBC-81F49D769C3EQ36802635-6BC3D37D-73DB-4F65-9B70-5771837C2335Q37246041-8B39374D-88E6-455D-B4E4-EA7A411B2ED2Q37662415-4C917735-7066-49F9-9C96-E887E1D9671FQ37692734-92BD8537-DAD9-4903-A57B-C450ABE0B2A5Q37866319-BED59601-BCC4-40BD-B1A8-61EEB90E21FCQ39473480-B8341C49-4F54-4CBE-8D09-764EEA5CF94AQ45093857-C15CEB75-13E3-4516-8BAA-58FDD2F99952
P2860
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@ast
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@en
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@nl
type
label
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@ast
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@en
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@nl
prefLabel
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@ast
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@en
Treatment with amprenavir alon ...... l Trials Group 347 Study Team.
@nl
P2093
P356
P1476
Treatment with amprenavir alon ...... al Trials Group 347 Study Team
@en
P2093
Caliendo AM
Currier JS
D'Aquila RT
DeGruttola V
Kuritzkes DR
P304
P356
10.1086/314668
P407
P577
1999-04-01T00:00:00Z